Articles related to CLINICAL STUDY

The authors investigated the effect of adding radiotherapy to neoadjuvant chemotherapy on survival in patients with Stage III-N2 non-small cell lung cancer. Analysis included 1,175 patients diagnosed between 2004 and 2015; 799 (68.0%) underwent neoadjuvant CRT and 376 (32.0%) underwent neoadjuvant CT. Adding radiotherapy to chemotherapy showed a slightly higher median OS than chemotherapy alone (51 vs. 47 months, respectively), and a higher median CSS (75 vs. 59 months, respectively). However, these differences were not statistically significant.

The review, which we covered previously, concluded that “oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios may be associated with short-term improvements in chronic pain and increased risk for dizziness and sedation.”

Dr. Mohyudding summarizes key findings ASCO reports, including updates on teclistamab in CAR-T, the DETERMINATION trial assessing auto-transplantation, cilta-cel (covered by HCN here), and the ATLAS study evaluating carfilzomib with lenalidomide and dexamethasone as maintenance vs. lenalidomide alone.

Data for this study came from Danish medical registries over a 20-year period for 247,305 people who visited a hospital or were prescribed antiviral medication for herpes zoster and 1,235,890 people who did not have the disease. These individuals were an average age 64. Up to 21 years later, 9.7% of those with vs. 10.3% of those without herpes zoster developed dementia.

The findings were presented at the 2022 Annual Meeting of the American Academy of Sleep Medicine and the Sleep Research Society. The researchers gathered the data from eight different studies that explored the safety profile of ashwagandha — an herb also known as Indian Ginseng, winter cherry, or poison gooseberry — as well as the clinical significance of its beneficial effects.

The authors concluded that, after reviewing the 13-year-study, “switching to LAIs during the first 3 years of treatment improved antipsychotic adherence, decreased relapses, and reduced long-term mortality.” With few studies available comparing the long-term effectiveness between patients who switched to LAIs and those who remained on oral antipsychotics (OAPs), they hope the evidence presented supports the benefits of early LAI treatment in schizophrenia.